Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Standard Biotools Inc (LAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: LAB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $2.38
1 Year Target Price $2.38
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.6% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 429.88M USD | Price to earnings Ratio - | 1Y Target Price 2.38 |
Price to earnings Ratio - | 1Y Target Price 2.38 | ||
Volume (30-day avg) 3 | Beta 1.5 | 52 Weeks Range 0.92 - 2.41 | Updated Date 06/29/2025 |
52 Weeks Range 0.92 - 2.41 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.32 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -78.24% | Operating Margin (TTM) -29.42% |
Management Effectiveness
Return on Assets (TTM) -11.63% | Return on Equity (TTM) -25.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 199733876 | Price to Sales(TTM) 2.53 |
Enterprise Value 199733876 | Price to Sales(TTM) 2.53 | ||
Enterprise Value to Revenue 1.18 | Enterprise Value to EBITDA -19.22 | Shares Outstanding 361241984 | Shares Floating 48281562 |
Shares Outstanding 361241984 | Shares Floating 48281562 | ||
Percent Insiders 1.53 | Percent Institutions 73.09 |
Analyst Ratings
Rating 2 | Target Price 2.38 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Standard Biotools Inc
Company Overview
History and Background
Standard Biotools Inc, formerly Fluidigm Corporation, was founded in 1999. The company focused on developing and manufacturing microfluidics-based systems for life science research. Over time, it evolved from providing tools for genomics and proteomics to offering solutions for single-cell biology and mass cytometry. In November 2022, Fluidigm Corporation announced it had changed its name to Standard BioTools Inc.
Core Business Areas
- Microfluidics-based Systems: Develops and manufactures integrated fluidic circuits (IFCs) and instruments used in various life science research applications, including single-cell genomics, proteomics, and immune profiling.
- Mass Cytometry: Offers CyTOFu00ae technology, a mass spectrometry-based technique used for high-parameter single-cell analysis.
- Reagents and Consumables: Provides reagents and consumables required for operating its instruments and platforms.
Leadership and Structure
Michael Egholm is the CEO. The company has a board of directors overseeing its strategic direction. Its organizational structure consists of various functional departments, including R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Heliosu2122 and CyTOFu00ae Systems: Mass cytometry platforms used for single-cell analysis. These instruments allow researchers to analyze a large number of cellular markers simultaneously. Competing technologies include flow cytometry (e.g., from BD Biosciences and Thermo Fisher Scientific) and other emerging single-cell analysis platforms. Market share information is difficult to ascertain precisely, but Standard Biotools holds a significant position in the mass cytometry niche.
- Biomarku2122 HD System: A microfluidics-based system for high-throughput gene expression analysis. This product competes with qPCR and other gene expression platforms from companies like Thermo Fisher Scientific and QIAGEN. Similar to CyTOF systems, precise market share data is unavailable, but it's a key product in Standard Biotools' portfolio.
Market Dynamics
Industry Overview
The life science tools and diagnostics market is characterized by innovation, driven by advancements in genomics, proteomics, and cell biology. The industry is highly competitive, with many players offering diverse technologies. Trends include increasing demand for single-cell analysis, personalized medicine, and high-throughput screening solutions.
Positioning
Standard Biotools holds a niche position with its mass cytometry and microfluidics platforms, offering unique capabilities in single-cell analysis and high-throughput applications. Its competitive advantage lies in its CyTOF technology and specialized microfluidic workflows. However, this positioning makes them dependent on life science research spending.
Total Addressable Market (TAM)
The total addressable market for life science tools and diagnostics is estimated to be in the tens of billions of USD. Standard Biotools addresses segments within this market, particularly in single-cell analysis. Given its relatively small market capitalization compared to larger competitors, it occupies a smaller position relative to the TAM.
Upturn SWOT Analysis
Strengths
- Proprietary CyTOFu00ae technology for single-cell analysis
- Expertise in microfluidics
- Established customer base in research institutions
- Innovation in high-parameter cellular analysis
Weaknesses
- Smaller scale compared to larger competitors
- Dependence on research funding cycles
- Limited product diversification
- History of financial instability
Opportunities
- Expanding applications of single-cell analysis in drug discovery and diagnostics
- Partnerships with pharmaceutical companies
- Developing new assays and workflows for existing platforms
- Geographic expansion into emerging markets
Threats
- Competition from larger life science tool companies
- Technological advancements by competitors
- Economic downturn impacting research funding
- Regulatory changes affecting diagnostics development
Competitors and Market Share
Key Competitors
- TMO
- DHR
- ILMN
Competitive Landscape
Standard Biotools faces competition from larger, more diversified life science tool companies. Its competitive advantage lies in specialized technologies, but it needs to scale and innovate to maintain its position. The competitors have more diversified product lines.
Major Acquisitions
DVS Sciences
- Year: 2014
- Acquisition Price (USD millions): 200
- Strategic Rationale: Acquisition of DVS Sciences expanded Standard Biotools' mass cytometry capabilities through the CyTOF technology platform.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been volatile, influenced by market adoption of its technologies and research funding trends.
Future Projections: Future growth projections depend on successful commercialization of its technologies, expansion into new markets, and strategic partnerships. Analyst estimates are necessary for precise projections.
Recent Initiatives: Recent initiatives include new product launches, partnerships, and efforts to improve operational efficiency.
Summary
Standard Biotools holds a unique position in the market with its specialized mass cytometry and microfluidics platforms but faces strong competition. Its proprietary technologies are a strength, but it needs to scale operations and navigate the volatile market. The company's dependence on life science research spending is a potential vulnerability that needs to be addressed through product diversification or expansion into adjacent markets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Analyst Estimates
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly, and actual results may differ from projections.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Standard Biotools Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2003-07-29 | President, CEO & Director Dr. Michael Egholm Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 814 | Website https://www.standardbio.com |
Full time employees 814 | Website https://www.standardbio.com | ||
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Standard BioTools Inc. was incorporated in 1999 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.